The global Dasatinib Drugs Market is estimated to be valued at US$ 4.35 billion in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Dasatinib is an oral medication used for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is classified as a tyrosine kinase ... Read more
